JP6856648B2 - Ｃｘｃｒ４受容体アンタゴニスト - Google Patents

Ｃｘｃｒ４受容体アンタゴニスト Download PDF

Info

Publication number
JP6856648B2
JP6856648B2 JP2018531058A JP2018531058A JP6856648B2 JP 6856648 B2 JP6856648 B2 JP 6856648B2 JP 2018531058 A JP2018531058 A JP 2018531058A JP 2018531058 A JP2018531058 A JP 2018531058A JP 6856648 B2 JP6856648 B2 JP 6856648B2
Authority
JP
Japan
Prior art keywords
methyl
alkyl
pyrimidin
imidazole
tetrahydroquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018531058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019502680A (ja
JP2019502680A5 (enExample
Inventor
グレッチェン・エム・シュローダー
トラム・エヌ・ハイン
ハイディ・エル・ペレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019502680A publication Critical patent/JP2019502680A/ja
Publication of JP2019502680A5 publication Critical patent/JP2019502680A5/ja
Application granted granted Critical
Publication of JP6856648B2 publication Critical patent/JP6856648B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018531058A 2015-12-15 2016-12-14 Ｃｘｃｒ４受容体アンタゴニスト Active JP6856648B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267649P 2015-12-15 2015-12-15
US62/267,649 2015-12-15
PCT/US2016/066575 WO2017106291A1 (en) 2015-12-15 2016-12-14 Cxcr4 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2019502680A JP2019502680A (ja) 2019-01-31
JP2019502680A5 JP2019502680A5 (enExample) 2020-01-23
JP6856648B2 true JP6856648B2 (ja) 2021-04-07

Family

ID=57755467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018531058A Active JP6856648B2 (ja) 2015-12-15 2016-12-14 Ｃｘｃｒ４受容体アンタゴニスト

Country Status (6)

Country Link
US (1) US10450318B2 (enExample)
EP (1) EP3390406A1 (enExample)
JP (1) JP6856648B2 (enExample)
KR (1) KR102738306B1 (enExample)
CN (1) CN108602829A (enExample)
WO (1) WO2017106291A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL309069A (en) 2017-02-21 2024-02-01 Univ Emory CXCR4 cytokine receptor modulators and related uses
CN109553604B (zh) * 2017-09-25 2021-08-27 盛世泰科生物医药技术(苏州)有限公司 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
EP3768256A4 (en) 2018-03-19 2021-11-24 Emory University PANTROPIC ENTRY INHIBITORS
CN115403510B (zh) * 2022-08-11 2023-04-25 南方医科大学 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127547D0 (en) * 2001-11-16 2002-01-09 Astrazeneca Ab Chemical compounds
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
MX2007002679A (es) * 2004-09-02 2007-05-16 Smithkline Beecham Corp Compuestos quimicos.
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
EP1838312A4 (en) * 2004-12-17 2010-01-20 Smithkline Beecham Corp CHEMICAL COMPOUNDS
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
WO2006122150A1 (en) 2005-05-10 2006-11-16 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
DK1910370T3 (en) 2005-07-22 2015-06-08 Lilly Co Eli PYRIDINQUINOLINE SUBSTITUTED PYRROLO [1,2-B] PYRAZOLE MONOHYDRATE AS TGF-BETA INHIBITOR
JP5294874B2 (ja) 2005-12-20 2013-09-18 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロ環
WO2007087549A2 (en) * 2006-01-25 2007-08-02 Smithkline Beecham Corporation Chemical compounds
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
EP2234620B1 (fr) 2008-01-03 2016-03-09 Université d'Aix-Marseille Tritherapie utilisable lors du traitement d'un patient infecte par le vih
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
ES2601226T3 (es) 2009-10-28 2017-02-14 Newlink Genetics Corporation Derivados de imidazol como inhibidores de IDO
RS58693B1 (sr) 2009-12-10 2019-06-28 Hoffmann La Roche Antitela koja poželjno vezuju ekstracelularni domen 4 humanog csf1r, i njihova primena
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
BR112012020372A8 (pt) 2010-03-05 2018-01-02 Hoffmann La Roche anticorpo que se liga ao csf-1r humano, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo recombinante
KR20200044999A (ko) 2010-05-04 2020-04-29 파이브 프라임 테라퓨틱스, 인크. Ｃｓｆ1ｒ에 결합하는 항체들
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
PH12020550156A1 (en) 2010-09-09 2024-01-15 Pfizer 4-1bb binding molecules
NO2694640T3 (enExample) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
US10023643B2 (en) 2011-12-15 2018-07-17 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
BR112014018961A8 (pt) 2012-02-06 2017-07-11 Genentech Inc Anticorpo isolado, anticorpo biespecífico, fragmento, ácido nucleico isolado, vetor, célula hospedeira, método de produção de anticorpos, composição farmacêutica, uso do anticorpo, método de tratamento, método de inibição e artigo industrializado
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
BR112014028013A2 (pt) 2012-05-11 2018-02-27 Five Prime Therapeutics Inc métodos para tratar uma condição associada com artrite reumatoide, artrite reumatoide, lesões de pele, nefrite lúpica, lúpus, uma condição inflamatória, distúrbio de cd16+, método para reduzir o número de monócitos cd16+, métodos para desacelerar a progressão de uma condição renal,de formação de panos e de perda óssea
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法

Also Published As

Publication number Publication date
JP2019502680A (ja) 2019-01-31
US10450318B2 (en) 2019-10-22
WO2017106291A1 (en) 2017-06-22
CN108602829A (zh) 2018-09-28
EP3390406A1 (en) 2018-10-24
KR102738306B1 (ko) 2024-12-03
US20180327409A1 (en) 2018-11-15
KR20180094036A (ko) 2018-08-22

Similar Documents

Publication Publication Date Title
CA2961740C (en) N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors
JP6639497B2 (ja) ブロモドメインインヒビターおよびその使用
JP7254821B2 (ja) 抗がん剤としての環状ジヌクレオチド
US20200392161A1 (en) Shp2 phosphatase inhibitors and methods of use thereof
TWI866258B (zh) 用於治療發炎性病症之新穎化合物及其醫藥組合物
WO2017117474A1 (en) Bifunctional compounds for her3 degradation and methods of use
JP2019516759A (ja) がんの処置のためのピラゾロピリジン誘導体
AU2017290748A1 (en) Pyrimidine-based antiproliferative agents
WO2017117473A1 (en) Bifunctional molescules for her3 degradation and methods of use
JP2017533248A (ja) ブロモドメインのインヒビターとしての置換ピロロピリジン
TW200908983A (en) Heterocyclic compounds and uses thereof
JP2021519308A (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
EP3256450B1 (en) Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof
TW201718546A (zh) 適用作pim激酶抑制劑之雜環化合物
JP2022511112A (ja) Ａｌｋ５阻害剤としてのナフチリジンおよびキノリン誘導体
EP3237415A1 (en) Tgf receptor antagonists
JP6856648B2 (ja) Ｃｘｃｒ４受容体アンタゴニスト
JP2021513562A (ja) 抗がん剤としての環状ジヌクレオチド
CN115443276A (zh) 吡啶并嘧啶酮衍生物及其作为芳烃受体调节剂的应用
KR20250113487A (ko) 화합물
WO2016198908A1 (en) Ror nuclear receptor modulators
JP2018528951A (ja) ＴＧＦβ受容体アンタゴニスト
JP2018525415A (ja) Ｔｇｆベータ受容体アンタゴニスト
US20130184273A1 (en) Bicyclic pyrimidines
JP2018526344A (ja) Ｔｇｆベータ受容体アンタゴニスト

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210309

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210318

R150 Certificate of patent or registration of utility model

Ref document number: 6856648

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250